Concepedia

Publication | Open Access

Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes

DOIFull Paper Access

110

Citations

30

References

2010

Year

Mikkael A. Sekeres, Alan F. List, David Cuthbertson, Ronald Paquette, Rebecca Ganetsky, D Latham, Katarina Paulic, Manuel Afable, Hussain I. Saba, Thomas P. Loughran,
Journal of Clinical Oncology

Abstract

The combination of lenalidomide and azacitidine is well tolerated with encouraging clinical activity. The go-forward dose is azacitidine 75 mg/m(2) on days 1 through 5 and lenalidomide 10 mg on days 1 through 21.

References

YearCitations

Page 1